File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: An intranasal influenza virus-vectored vaccine prevents SARS-CoV-2 replication in respiratory tissues of mice and hamsters

TitleAn intranasal influenza virus-vectored vaccine prevents SARS-CoV-2 replication in respiratory tissues of mice and hamsters
Authors
Issue Date12-Apr-2023
PublisherNature Research
Citation
Nature Communications, 2023, v. 14, n. 1 How to Cite?
Abstract

Current available vaccines for COVID-19 are effective in reducing severe diseases and deaths caused by SARS-CoV-2 infection but less optimal in preventing infection. Next-generation vaccines which are able to induce mucosal immunity in the upper respiratory to prevent or reduce infections caused by highly transmissible variants of SARS-CoV-2 are urgently needed. We have developed an intranasal vaccine candidate based on a live attenuated influenza virus (LAIV) with a deleted NS1 gene that encodes cell surface expression of the receptor-binding-domain (RBD) of the SARS-CoV-2 spike protein, designated DelNS1-RBD4N-DAF. Immune responses and protection against virus challenge following intranasal administration of DelNS1-RBD4N-DAF vaccines were analyzed in mice and compared with intramuscular injection of the BioNTech BNT162b2 mRNA vaccine in hamsters. DelNS1-RBD4N-DAF LAIVs induced high levels of neutralizing antibodies against various SARS-CoV-2 variants in mice and hamsters and stimulated robust T cell responses in mice. Notably, vaccination with DelNS1-RBD4N-DAF LAIVs, but not BNT162b2 mRNA, prevented replication of SARS-CoV-2 variants, including Delta and Omicron BA.2, in the respiratory tissues of animals. The DelNS1-RBD4N-DAF LAIV system warrants further evaluation in humans for the control of SARS-CoV-2 transmission and, more significantly, for creating dual function vaccines against both influenza and COVID-19 for use in annual vaccination strategies.


Persistent Identifierhttp://hdl.handle.net/10722/331495
ISSN
2021 Impact Factor: 17.694
2020 SCImago Journal Rankings: 5.559
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorDeng, Shaofeng-
dc.contributor.authorLiu, Ying-
dc.contributor.authorTam, Rachel Chun-Yee-
dc.contributor.authorChen, Pin-
dc.contributor.authorZhang, Anna Jinxia-
dc.contributor.authorMok, Bobo Wing-Yee-
dc.contributor.authorLong, Teng-
dc.contributor.authorKukic, Anja-
dc.contributor.authorZhou, Runhong-
dc.contributor.authorXu, Haoran-
dc.contributor.authorSong, Wenjun-
dc.contributor.authorChan, Jasper Fuk-Woo-
dc.contributor.authorTo, Kelvin Kai-Wang-
dc.contributor.authorChen, Zhiwei-
dc.contributor.authorYuen, Kwok-Yung-
dc.contributor.authorWang, Pui-
dc.contributor.authorChen, Honglin-
dc.date.accessioned2023-09-21T06:56:20Z-
dc.date.available2023-09-21T06:56:20Z-
dc.date.issued2023-04-12-
dc.identifier.citationNature Communications, 2023, v. 14, n. 1-
dc.identifier.issn2041-1723-
dc.identifier.urihttp://hdl.handle.net/10722/331495-
dc.description.abstract<p>Current available vaccines for COVID-19 are effective in reducing severe diseases and deaths caused by SARS-CoV-2 infection but less optimal in preventing infection. Next-generation vaccines which are able to induce mucosal immunity in the upper respiratory to prevent or reduce infections caused by highly transmissible variants of SARS-CoV-2 are urgently needed. We have developed an intranasal vaccine candidate based on a live attenuated influenza virus (LAIV) with a deleted NS1 gene that encodes cell surface expression of the receptor-binding-domain (RBD) of the SARS-CoV-2 spike protein, designated DelNS1-RBD4N-DAF. Immune responses and protection against virus challenge following intranasal administration of DelNS1-RBD4N-DAF vaccines were analyzed in mice and compared with intramuscular injection of the BioNTech BNT162b2 mRNA vaccine in hamsters. DelNS1-RBD4N-DAF LAIVs induced high levels of neutralizing antibodies against various SARS-CoV-2 variants in mice and hamsters and stimulated robust T cell responses in mice. Notably, vaccination with DelNS1-RBD4N-DAF LAIVs, but not BNT162b2 mRNA, prevented replication of SARS-CoV-2 variants, including Delta and Omicron BA.2, in the respiratory tissues of animals. The DelNS1-RBD4N-DAF LAIV system warrants further evaluation in humans for the control of SARS-CoV-2 transmission and, more significantly, for creating dual function vaccines against both influenza and COVID-19 for use in annual vaccination strategies.<br></p>-
dc.languageeng-
dc.publisherNature Research-
dc.relation.ispartofNature Communications-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.titleAn intranasal influenza virus-vectored vaccine prevents SARS-CoV-2 replication in respiratory tissues of mice and hamsters-
dc.typeArticle-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1038/s41467-023-37697-1-
dc.identifier.scopuseid_2-s2.0-85152347580-
dc.identifier.volume14-
dc.identifier.issue1-
dc.identifier.eissn2041-1723-
dc.identifier.isiWOS:001003644100007-
dc.identifier.issnl2041-1723-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats